About Biosynex
Biosynex is a publicly listed company based in Strasbourg (France) founded in 2005. Professional rapid diagnostic tests for diseases are manufactured by Biosynex. The company has 486 employees. Biosynex has completed 8 acquisitions, including BigiX Pharma, Bixi Pharma and Chembio. Biosynex offers products and services including Rapid Diagnostic Tests, Ampliflash, and Ampliquick. Its focus areas include Diversified Diagnostics. Its legal entity is BIOSYNEX SA.
Company details
Biosynex (previously DIMA) is the manufacturer and provider of rapid membrane tests in the in-vitro diagnostic market. Its professional diagnostic products include Rapid diagnostic tests (RDTs) to detect an infection (HIV, malaria, mononucleosis, tonsillitis), an immune status (tetanus immunity), a physiological situation (pregnancy), an acute pathological situation (rupture of fetal membranes, myocardial infarction) or the presence of drugs in urine or saliva Blot tests (Western Blot or immunoblot) to indicate the presence or absence of antibodies and Real-time PCR (qPCR) enables the quantitative measure of DNA and ARN molecules. It also develops self-diagnostic tests for pregnancy, drug testing, blood pressure and glucose monitoring. It also provides oral care, reading glasses and foot care products.
- Headquarters Strasbourg, France
- Employees 486
- Stage Public
- SectorsHealthcare
- Website biosynex.com
- Social LinkedIn Facebook YouTube
- Legal Name Biosynex Sa
- Annual Revenue$111.85 M (USD)-5.9as on Dec 31, 2025
- Net Profit-$68.41 M (USD)-34.37as on Dec 31, 2025
- EBITDA$9.99 M (USD)as on Dec 31, 2025
- Latest Funding Round$1.11M (USD), Debt – Conventional
Jul 2016
- Investors
- Employee Count486
- Investments & AcquisitionsBigiX Pharma
& 7 more
Products & Services of Biosynex
Biosynex offers a comprehensive portfolio of products and services, including Rapid Diagnostic Tests, Ampliflash, and Ampliquick.
Tests for quick detection of medical conditions.
Device for molecular biology testing and analysis.
System for rapid PCR testing in healthcare settings.
Apps and channels of Biosynex
its YouTube channel Laboratoire Biosynex has 6.45K subscribers and 30 videos.
Videos from Biosynex
The most watched videos on Biosynex's YouTube channel, Laboratoire Biosynex (6.45K subscribers). Click a video to play it here.
More on Laboratoire Biosynex.
Funding Insights of Biosynex
- Total Rounds 2
- Last Round Debt – Conventional — $1.11M
- First Round $2.83M
(Nov 2015)
- Investors Count 1
All 2 funding rounds of Biosynex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2016 | $1.11M | Debt – Conventional | – | – | |
| Nov 2015 | $2.83M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Biosynex
Biosynex has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bpifrance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Corporate consultancy, advisory, and funding services are provided to businesses. | 2012 | bpifrance.com | Maisons Alfort, France |
Investor details for Biosynex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biosynex
9 people are tracked at Biosynex (2 in leadership, 7 in team); the tracked headcount is 486.
| Name | Role | Group |
|---|---|---|
Larry Abensur | CEO/Founder | Leadership |
Muriel Bardet | Group HR Director | Leadership |
Nancy Vanherle | Farmaceutisch Accountmanager | Team |
Raphael Dupont | Directeur Marketing International | Team |
Thierry Paper | Directeur Général | Team |
Rachel Thomann | Export Area Manager | Team |
Chanael Sellam | Directrice Relation Clients Europe | Team |
Gaël Lévy | Directeur Opérationnel | Team |
Sarah Abessera | Graphiste | Team |
Complete people profiles for Biosynex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Biosynex
Biosynex is a publicly listed company on the EURONEXT with ticker symbol ALBIO in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Mar 2011
- Listed onEuronext: ALBIO
- Listed entityBiosynex SA
- Exchange sectorHealth technology
- ISINFR0011005933
- Share price0.88 EUR (+3.29% on the day) · 2026-10-14
- Market capitalisation15,461,648.00 EUR
- Volume (last session)8,608
Financials of Biosynex
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 95.2M EUR | -58.2M EUR | 8.5M EUR |
| 2024 | 101.2M EUR | -43.3M EUR | -68,000 EUR |
| 2023 | 93.0M EUR | -37.0M EUR | -11.6M EUR |
| 2022 | 196.6M EUR | 15.6M EUR | 55.2M EUR |
| 2021 | 382.5M EUR | 104.0M EUR | 147.3M EUR |
Detailed financial statements for Biosynex
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biosynex
Biosynex has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include BigiX Pharma, Bixi Pharma and Chembio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Point-of-care diagnostic devices for immunoassay tests are provided to clinicians. | procisedx.com | San Diego, United States | 2018 | Jun 2023 | •••• | |
Proprietary immunoassay platform is utilized for infectious disease diagnostics. | chembio.com | Medford, United States | 1986 | Jan 2023 | •••• | |
Rapid diagnostic test kits are manufactured and healthcare solutions provided. | medkoncept.dk | Hellerup, Denmark | 2017 | Dec 2022 | •••• | |
Digital remote health monitoring devices are provided to healthcare providers. | doc2u.fr | Toulouse, France | 2019 | Oct 2022 | •••• | |
Manufacturer of half cylinder cushion, antibacterial wedge & sanitizers | bigix.it | Asti, Italy | 2017 | Sep 2022 | •••• | |
Thermometers, hot water bottles, and mosquito repellents are manufactured. | bigixpharma.com | Asti, Italy | 2017 | Sep 2022 | •••• | |
Pest control products are branded and distributed by PARA’KITO. | parakito.com | Fort Lauderdale, United States | 2006 | Apr 2022 | •••• | |
Developer of reagents for microbiology | sr2b.fr | Angers, France | 1984 | Jun 2017 | •••• |
Complete acquisition details for Biosynex
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Biosynex
12 dated milestones of Biosynex across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Biosynex is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $2.8M.
- Funding Latest funding round, Debt – Conventional, of $1.1M.
- Acquisition Acquires SR2B.
- Acquisition Acquires PARA’KITO.
- Acquisition Acquires BigiX Pharma.
- Acquisition Acquires Bixi Pharma.
- Acquisition Acquires Doc2u.
- Acquisition Acquires Medkoncept.
- Acquisition Acquires Chembio.
- Acquisition Acquires ProciseDx.
Web traffic of Biosynex
The website of Biosynex (biosynex.com) receives about 9.3K visits a month.
- Monthly visits9.3K
▲ 38.5% vs previous month
Websites whose visitors overlap most with Biosynex. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| laboratoire-arrow.com | 100% | 3.7K | #4,344,068 | View details | |
| frafito.net | 90% | #4,809,779 | View details | ||
farlamedical.be | farlamedical.be | 84% | #2,978,748 | – | |
| itechmedicaldivision.com | 80% | #498,948 | View details | ||
| bastideleconfortmedical.com | 80% | 152.1K | #186,813 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for Biosynex
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biosynex
Complete news archive for Biosynex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biosynex
Biosynex was founded in 2005 and raised its 1st funding round 10 years after it was founded.
Biosynex is headquartered in Strasbourg, France. It is registered at Strasbourg, Grand Est, France.
Biosynex has 486 employees.
Annual revenue of Biosynex is $111.85M as on Dec 31, 2025.
Biosynex (previously DIMA) is the manufacturer and provider of rapid membrane tests in the in-vitro diagnostic market. Its professional diagnostic products include Rapid diagnostic tests (RDTs) to detect an infection (HIV, malaria, mononucleosis, tonsillitis), an immune status (tetanus immunity), a physiological situation (pregnancy), an acute pathological situation (rupture of fetal membranes, myocardial infarction) or the presence of drugs in urine or saliva Blot tests (Western Blot or immunoblot) to indicate the presence or absence of antibodies and Real-time PCR (qPCR) enables the quantitative measure of DNA and ARN molecules. It also develops self-diagnostic tests for pregnancy, drug testing, blood pressure and glucose monitoring. It also provides oral care, reading glasses and foot care products.
Biosynex offers Rapid Diagnostic Tests, Ampliflash, and Ampliquick.
Yes, Biosynex is publicly traded on EURONEXT under the ticker symbol ALBIO.
Biosynex has made 8 acquisitions, including BigiX Pharma, Bixi Pharma, and Chembio.
Biosynex has 1 investor. Key investors include Bpifrance.
Biosynex operates through Biosynex Sa.